Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iSPOT-A study of biomarkers and methylphenidate response in children and adolescents with ADHD
ACTRN12609000271202Phase 4Recruiting
- Sponsor
- Brain Resource
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, open-label trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 cohorts), sponsored by Brain Resource. Primary endpoint: Markers predicting acute methylphenidate treatment response. Started Apr 2009; status: recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ACTRN12609000271202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000271202.